Commerzbank AG Reaffirms “Buy” Rating for Qiagen NV (QGEN)
Qiagen NV (NASDAQ:QGEN)‘s stock had its “buy” rating reaffirmed by stock analysts at Commerzbank AG in a report released on Wednesday.
Several other equities analysts have also commented on the company. Morgan Stanley set a $30.00 price target on Qiagen NV and gave the stock a “buy” rating in a research report on Sunday, September 11th. Jefferies Group reissued a “hold” rating on shares of Qiagen NV in a research report on Thursday, August 4th. JPMorgan Chase & Co. reissued a “hold” rating and set a $27.00 price target on shares of Qiagen NV in a research report on Thursday, November 3rd. DZ Bank AG reissued a “buy” rating on shares of Qiagen NV in a research report on Friday, July 29th. Finally, Zacks Investment Research raised Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Wednesday, September 14th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.60.
Qiagen NV (NASDAQ:QGEN) opened at 27.76 on Wednesday. Qiagen NV has a 52 week low of $19.94 and a 52 week high of $28.50. The stock has a market capitalization of $6.50 billion, a price-to-earnings ratio of 55.52 and a beta of 1.07. The firm has a 50-day moving average of $26.44 and a 200 day moving average of $24.47.
Qiagen NV (NASDAQ:QGEN) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.01. The business had revenue of $338.70 million for the quarter, compared to analyst estimates of $335.46 million. Qiagen NV had a return on equity of 9.34% and a net margin of 8.96%. The company’s revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.27 EPS. On average, analysts anticipate that Qiagen NV will post $1.03 EPS for the current year.
Several large investors have recently modified their holdings of the stock. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Qiagen NV during the second quarter worth $116,000. First Mercantile Trust Co. bought a new position in shares of Qiagen NV during the second quarter worth approximately $126,000. Societe Generale bought a new position in shares of Qiagen NV during the second quarter worth approximately $152,000. SG Americas Securities LLC increased its position in shares of Qiagen NV by 9.9% in the second quarter. SG Americas Securities LLC now owns 6,977 shares of the company’s stock worth $152,000 after buying an additional 629 shares during the last quarter. Finally, Riverhead Capital Management LLC increased its position in shares of Qiagen NV by 402.2% in the third quarter. Riverhead Capital Management LLC now owns 5,800 shares of the company’s stock worth $159,000 after buying an additional 4,645 shares during the last quarter. Institutional investors and hedge funds own 57.22% of the company’s stock.
Qiagen NV Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Receive News & Stock Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related stocks with our FREE daily email newsletter.